Introduction {#s1}
============

Comparatively isolated diastolic dysfunction or stiffness of the left ventricle is a chronic pathological condition that evolves into heart failure with preserved ejection fraction (HFpEF). An increasing body of evidence reports that HFpEF is frequent in women and the elderly ([@B1]--[@B3]). In fact, HFpEF accounts for about half the cases of heart failure (HF) and is the leading cause of hospital admission in patients over 65 years of age. Although individuals with HFpEF exhibit similar mortality rates as those that have heart failure with reduced ejection fraction (HFrEF) or impaired cardiac contractility, there are currently no proven effective medicines for this condition ([@B1]--[@B6]) Thus, HFpEF is a major unmet medical need and there is an urgency for new therapeutic approaches and strategies that target mechanisms specific for HFpEF. Notably, HFpEF is associated with the co-presence of several comorbidities ([@B7]). Particularly among younger persons, HFpEF is associated with the interrelated cardiovascular risk factors of obesity and type II diabetes ([@B8]). Given the obesity epidemic that is attributed to the Western diet and lifestyle, and an aging population, it is not surprising then that HFpEF is predicted to be the primary cause of HF within a decade.

A clinical cardiac phenotype like HFpEF is difficult to study due to its complex nature that involves genetic, molecular, and environmental factors. Ultimately, increased cardiac stiffness in HFpEF is thought to arise from loss of nitric oxide signaling due to microvascular inflammation, increased cardiac fibrosis, and a concentric pattern of cardiac hypertrophy that also compromises ventricular chamber size. Several animal models are characterized by diastolic dysfunction and have been used to study HFpEF. However, it is unclear what these different models have in common, or their differences, as far as disease etiology and cardiac remodeling, which could reveal common or fundamental signaling pathways representing potential therapeutic targets. Given the rapid growth of experimental genetic data in repositories, such as Gene Expression Omnibus (GEO), data mining is a powerful approach that can create countless openings for holistic investigations using assorted studies.

Our *in silico* investigation aimed towards identifying novel pathological pathways in the heart that are relevant for the development of HFpEF. In our study, we make use of public datasets, to perform top-notch biostatistics and bioinformatics that aid in deciphering genetic events that drive the detrimental cardiac remodeling in three rodent models with diastolic dysfunction, the Dahl salt sensitive rat (Dahl/SS), the spontaneously hypertensive heart failure (SHHF) rat, and the type I diabetic rat.

Methods {#s2}
=======

GEO Search {#s2-1}
----------

GEO search for microarray data from heart in three animal models with underlying diastolic disfunction: the Dahl Salt Sensitive (GSE66617), the Spontaneous Hypertensive Heart Failure (GSE2876), and the Streptozotocin/Diabetes1 (GSE6880). The total number of samples of each dataset was *n* = 28, 10 and 6 for Dahl SS, SHHF, and diabetic, respectively.

Rat Models Selected {#s2-2}
-------------------

Dahl Salt Sensitive (SS) rats were fed either a 0.3% NaCl (normal salt, NS, control group) or with 8% NaCl (high salt, HS, heart failure group) diet until evidence of left ventricular dysfunction ([@B9]). The authors extracted total RNA from left ventricular samples at the stage of heart failure using mirVana (Applied Biosystems) according to the manufacturer's instructions ([@B9]). Three samples from each group were pooled. cDNA and Amino Allyl aRNA was synthesized by Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion). CyeDye Coupling and fragmentation were performed according to the manufacturer's protocol (TORAY Industries, Inc, Tokyo, Japan). Samples were then hybridized for 16 h at 37°C on a Rat Oligo chip 20 K (TORAY Industries, Inc, Tokyo, Japan). Scanning was performed on a 3D-Gene Scanner (Toray Industries Inc., Tokyo, Japan).

Spontaneously Hypertensive and Heart Failure-prone (SHHF) rats were obtained by backcrossing a Koletsky obese rat to a Spontaneously Hypertensive Rat (SHR/N) ([@B10]). Controls were 4 months old lean rats and heart failure rats were 10 months old obese rats ([@B10]). Total RNA was extracted with TRIzol (GIBCO) according to the manufacturer's protocol and reverse transcribed with Superscript enzyme (Invitrogen) and labelling the cDNA with ^33^P. Purification of cDNA was performed using NucleoSpin Extract (Macherey-Nagel). The kit Array-Advantage GF (Ambion) was used to hybridize the samples into pan-genomic macroarray nylon membranes (RZPD, Berlin), which were exposed for 24 h and scanned with a Scan Typhoon 9400 (resolution at 50 µm per pixel).

Diabetic rats were induced with streptozotocin injection at 8 weeks, which led to a model of insulin-deficient type 1 diabetes ([@B11]). Rats were sacrificed at 12 weeks (so diabetic for 4 weeks) ([@B11]). RNA was extracted with TRIzol (GIBCO) and cleaned with RNeasy total RNA mini kit (Qiagen). Superscript II (Life Technologies) was used for first strand cDNA synthesis. Subsequent steps necessary to hybridize the samples on Affymetrix RAE 230A microarrays were performed according to the Affymetrix protocol. Arrays were scanned on an Hewlett-Packard Gene Array scanner.

Microarray Data Analysis {#s2-3}
------------------------

GEO2R has been used as a base for the analysis of the Dahl/SS dataset, whereas the Limma package was used to analyze the Diabetic and SHHF model. Distribution of value data for the Samples used was calculated (data not shown) and median-centered values indicated that the data were normalized and cross-comparable. Fold-changes per group were calculated using average Disease/Control. Statistical significance of differences in gene expression was assessed using the nonparametric Wilcoxon signed-rank test and the log2-transformed data.

The differentially expressed genes (DEGs) with fold-change (FC) \>2 and \< −2 and adjusted *p*-value \< 0.05 have been selected for Dahl/SS and SHHF, whereas FC \>1.5 and FC \< −1.5 was chosen for Diabetic 1 due to the high level of confidence \[false discovery rate (FDR) = 0, ([Figure S1](#SF1){ref-type="supplementary-material"})\] at *p*-values \< 0.05.

The Benjamini and Hochberg false discovery rate method was selected by default because it is the most commonly used adjustment for microarray data and provides a good balance between discovery of statistically significant genes and limitation of false positives.

Gene Set Enrichment Analysis (GSEA) was performed for each of the three datasets using QIAGEN's Ingenuity Pathway Core Analysis (IPA, QIAGEN Redwood City, [www.qiagen.com/ingenuity](www.qiagen.com/ingenuity)). The Ingenuity Knowledge Base was used as reference set and both direct and indirect experimentally confirmed relationships from humans and rodents. Z-scores of \>2 or \< −2 were considered significant. Details about the statistics used can be found at the Ingenuity website: []()<http://www.ingenuity.com/products/ipa#/?tab=resources>.

Genes have been mapped in IPA for further analysis (see [Table 1](#T1){ref-type="table"}).

###### 

DEGs analysed in IPA

  **GEO Series (GSE)**   **Rat Model**                **Condition**           **Cases**   **Controls**   **DEGs**   **IPA Mapped IDs**   **IPA Unmapped IDs**   
  ---------------------- ---------------------------- ----------------------- ----------- -------------- ---------- -------------------- ---------------------- ----
  GSE66617               Dahl/SS                      Systemic Hypertension   3           3              222        28                   80                     53
  GSE2876                SHHF                         Hypertension,Obesity    17          11             81         114                  172                    8
  GSE6880                Streptozotocin (Diabetes1)   Diabetes,Obesity        3           3              593        546                  1,062                  62

Results {#s3}
=======

Animal Models of HFpEF {#s3-1}
----------------------

Our GEO search for published microarray data on hearts from animal models of diastolic dysfunction was narrowed down to the Dahl/SS, streptozotocin-induced diabetic, and SHHF rat models. [Table 1](#T1){ref-type="table"} shows the overall number of DEGs found for each animal model. The top 250 DEGs (genes with the smallest *p*-value) calculated with GEO2R indicated that the diabetic model has 20 genes in common with the Dahl/SS and 15 with the SHHF models ([Table 2](#T2){ref-type="table"}). Given the high cumulative number of significant calls for the diabetic rat model ([Figure S1](#SF1){ref-type="supplementary-material"}) we included up to 1,139 genes with a local FDR (false discovery rate) of 0.

###### 

Common DEGs among the HRpEF animal models

  **Animal models**         **Gene names**                                      **Entrez Gene Name**             **Location**              **Type**
  ------------------------- --------------------------------------------------- -------------------------------- ------------------------- ----------------------------
  **Dahl/SS and SHHF**      ADRA1D                                              Adrenoceptor alpha 1D            Plasma Membrane           G-protein coupled receptor
  AKIP1                     A-kinase interacting protein 1                      Nucleus                          Other                     
  ALOX15                    Arachidonate 15-lipoxygenase                        Cytoplasm                        Enzyme                    
  ANKRD23                   Ankyrin repeat domain 23                            Nucleus                          Other                     
  APLN                      Apelin                                              Extracellular Space              Other                     
  Bex1/LOC100912195         Brain expressed, X-linked 1                         Cytoplasm                        Other                     
  CDC25B                    Cell division cycle 25B                             Nucleus                          Phosphatase               
  COL8A1                    Collagen type VIII alpha 1 chain                    Extracellular Space              Other                     
  EPN3                      Epsin 3                                             Cytoplasm                        Other                     
  FHL1                      Four and a half LIM domains 1                       Cytoplasm                        Other                     
  FIBIN                     Fin bud initiation factor homolog (zebrafish)       Cytoplasm                        Other                     
  FXYD3                     FXYD domain containing ion transport regulator 3    Plasma Membrane                  Other                     
  Hamp                      Hepcidin antimicrobial peptide                      Extracellular Space              Other                     
  MS4A6A                    Membrane spanning 4-domains A6A                     Other                            Other                     
  MYH6                      Myosin heavy chain 6                                Cytoplasm                        Enzyme                    
  MYH7                      Myosin heavy chain 7                                Cytoplasm                        Enzyme                    
  NPPA                      Natriuretic peptide A                               Extracellular Space              Other                     
  NUPR1                     Nuclear protein 1, transcriptional regulator        Nucleus                          Transcription regulator   
  SFRP1                     Secreted frizzled related protein 1                 Plasma Membrane                  Transmembrane receptor    
  TRDN                      Triadin                                             Cytoplasm                        Other                     
  **Diabetes 1 and SHHF**   COL4A1                                              Collagen type IV alpha 1 chain   Extracellular Space       Other
  COL6A1                    Collagen type VI alpha 1 chain                      Extracellular Space              Other                     
  CREG1                     Cellular repressor of E1A stimulated genes 1        Nucleus                          Transcription regulator   
  CXCL3                     Chemokine (C-X-C motif) ligand 3                    Extracellular Space              Cytokine                  
  ELK3                      ELK3, ETS transcription factor                      Nucleus                          Transcription regulator   
  FAM49B                    Family with sequence similarity 49 member B         Extracellular Space              Other                     
  KANK2                     KN motif and ankyrin repeat domains 2               Nucleus                          Transcription regulator   
  KLF9                      Kruppel like factor 9                               Nucleus                          Transcription regulator   
  PIK3IP1                   Phosphoinositide-3-kinase interacting protein 1     Cytoplasm                        Other                     
  PLXND1                    Plexin D1                                           Plasma Membrane                  Transmembrane receptor    
  PTP4A2                    Protein tyrosine phosphatase type IVA, member 2     Cytoplasm                        Phosphatase               
  PTPN3                     Protein tyrosine phosphatase, non-receptor type 3   Cytoplasm                        Phosphatase               
  SIPA1L1                   Signal induced proliferation associated 1 like 1    Cytoplasm                        Other                     
  WDR45                     WD repeat domain 45                                 Other                            Other                     
  ZFP532                    Zinc finger protein 532                             Nucleus                          Other                     

Cardiac Genes Assessed by GSEA {#s3-2}
------------------------------

IPA generated annotations were derived for the DEGs in each of the datasets. Among the three animal models we selected, only the Dahl/SS and SHHF models showed that over-represented genes (*n* = 25 and *n* = 26, respectively) determined by DEG analysis are strongly associated with cardiovascular diseases. The cardiovascular disease phenotypes of these two models appear to have different gene datasets as none of the DEGs identified are in common ([Table 3](#T3){ref-type="table"}). SHHF with 17 genes is also associated with metabolic disease, whereas the diabetic rat is solely associated with metabolic disease with 175 genes ([Table 4](#T4){ref-type="table"}). These two datasets appear to have in common phosphoinositide-3-kinase interacting protein 1 (*PIK3IP1*), a negative regulator of PI3K and physiological, but not pathological cardiac hypertrophy ([@B12]).

###### 

DEGs linked to cardiovascular disease

  **Dahl/SS**   **SHHF**                                                                                                
  ------------- ---------- --------------------- ---------------------------- --------- --------- --------------------- -------------------------
  10.703        ACMSD      Cytoplasm             Enzyme                       --1.55    ACBD3     Cytoplasm             Other
  10.591        ADRA1D     Plasma Membrane       G-protein coupled receptor   --0.99    AGER      Plasma Membrane       Transmembrane receptor
  12.82         ALAS2      Cytoplasm             Enzyme                       --1.237   AOC3      Plasma Membrane       Enzyme
  11.761        ALOX15     Cytoplasm             Enzyme                       --1.016   ATF6      Cytoplasm             Transcription regulator
  11.65         APLN       Extracellular Space   Other                        1.474     ATP2B1    Plasma Membrane       Transporter
  7.917         COL8A1     Extracellular Space   Other                        1.21      C1QTNF5   Plasma Membrane       Transmembrane receptor
  8.196         CTGF       Extracellular Space   Growth factor                --1.764   C1S       Extracellular Space   Peptidase
  8.809         EGR2       Nucleus               Transcription regulator      1.457     CBFB      Nucleus               Transcription regulator
  9.589         FHL1       Cytoplasm             Other                        --1.103   COL4A1    Extracellular Space   Other
  8.642         FIBIN      Cytoplasm             Other                        1.147     COL6A1    Extracellular Space   Other
  12.541        GPRC5A     Plasma Membrane       G-protein coupled receptor   --1.194   CXCL16    Extracellular Space   Cytokine
  7.862         MYBPC2     Cytoplasm             Other                        --1.405   FAM49B    Extracellular Space   Other
  10.981        MYH6       Cytoplasm             Enzyme                       1.929     KLF9      Nucleus               Transcription regulator
  9.756         MYH7       Cytoplasm             Enzyme                       2.108     LMOD1     Cytoplasm             Other
  11.984        NPPA       Extracellular Space   Other                        --1.457   NRARP     Nucleus               Transcription regulator
  9.867         PDLIM5     Cytoplasm             Other                        --1.421   PARP1     Nucleus               Enzyme
  12.151        POSTN      Extracellular Space   Other                        1.444     PIK3IP1   Cytoplasm             Other
  11.873        RHCE/RHD   Plasma Membrane       Transporter                  --1.279   PLXND1    Plasma Membrane       Transmembrane receptor
  8.419         S100A8     Cytoplasm             Other                        --1.668   POLB      Nucleus               Enzyme
  8.976         S100A9     Cytoplasm             Other                        --1.381   PRNP      Plasma Membrane       Other
  7.527         TGFB2      Extracellular Space   Growth factor                --1.427   PSEN1     Plasma Membrane       Peptidase
  12.04         THBS4      Extracellular Space   Other                        1.257     PTGS1     Cytoplasm             Enzyme
  8.753         TIMP1      Extracellular Space   Cytokine                     1.394     SLC6A1    Plasma Membrane       Transporter
  11.594        TRDN       Cytoplasm             Other                        1.267     SV2A      Cytoplasm             Transporter
  12.207        WISP2      Extracellular Space   Growth factor                --2.219   TUBA1C    Cytoplasm             Other
                                                                              --1.004   ZNF532    Nucleus               Other

Green indicates the downregulated gene; red indicates the upregulated gene.

###### 

DEGs associated with metabolic disease

  **SHHF**   **Diabetes 1**                                                                                             
  ---------- ---------------- --------------------- ------------------------ --------- ---------- --------------------- -----------------------------------
  --0.99     AGER             Plasma Membrane       Transmembrane receptor   1.136     ABAT       Cytoplasm             Enzyme
  --1.454    ARSA             Cytoplasm             Enzyme                   --0.602   ABCC8      Plasma Membrane       Transporter
  1.534      ARSB             Cytoplasm             Enzyme                   0.92      ABCG8      Plasma Membrane       Transporter
  --1.764    C1S              Extracellular Space   Peptidase                0.629     ACAA2      Cytoplasm             Enzyme
  --1.194    CXCL16           Extracellular Space   Cytokine                 --0.776   ACAT2      Cytoplasm             Enzyme
  --1.621    DCX              Cytoplasm             Other                    --0.697   ADAM10     Plasma Membrane       Peptidase
  --1.697    LIG1             Nucleus               Enzyme                   --1.219   ADRA1B     Plasma Membrane       G-protein coupled receptor
  --1.204    NAT8B            Cytoplasm             Enzyme                   --3.176   ADRA1D     Plasma Membrane       G-protein coupled receptor
  --1.234    PDK1             Cytoplasm             Kinase                   --0.691   AKT1       Cytoplasm             Kinase
  1.444      PIK3IP1          Cytoplasm             Other                    --1.784   ALDH1A1    Cytoplasm             Enzyme
  --1.668    POLB             Nucleus               Enzyme                   --1.459   ALDH1L1    Cytoplasm             Enzyme
  --1.381    PRNP             Plasma Membrane       Other                    2.492     ALOX15     Cytoplasm             Enzyme
  --1.427    PSEN1            Plasma Membrane       Peptidase                2.875     AMY2B      Extracellular Space   Enzyme
  1.257      PTGS1            Cytoplasm             Enzyme                   --1.363   APLN       Extracellular Space   Other
  --1.237    SNRNP70          Nucleus               Other                    --1.284   APOBEC1    Cytoplasm             Enzyme
  1.267      SV2A             Cytoplasm             Transporter              --2.127   ARG1       Cytoplasm             Enzyme
  --2.219    TUBA1C           Cytoplasm             Other                    --0.711   ATP1A2     Plasma Membrane       Transporter
  --1.378    UQCC2            Cytoplasm             Other                    2.899     ATP1A4     Plasma Membrane       Transporter
                                                                             --1.124   ATP7A      Plasma Membrane       Transporter
                                                                             --2.395   AVPR2      Plasma Membrane       G-protein coupled receptor
                                                                             1.312     BCL2L1     Cytoplasm             Other
                                                                             0.848     BMP2       Extracellular Space   Growth factor
                                                                             1.046     BRCA1      Nucleus               Transcription regulator
                                                                             --0.927   CA4        Plasma Membrane       Enzyme
                                                                             1.356     CACNA1B    Plasma Membrane       Ion channel
                                                                             1.014     CACNA1S    Plasma Membrane       Ion channel
                                                                             --2.783   CASP8      Nucleus               Peptidase
                                                                             0.704     CAT        Cytoplasm             Enzyme
                                                                             --0.717   CAV1       Plasma Membrane       Transmembrane receptor
                                                                             0.795     CBLB       Nucleus               Enzyme
                                                                             0.951     Ccl2       Extracellular Space   Cytokine
                                                                             --0.861   CCNB1      Cytoplasm             Kinase
                                                                             --1.161   CCND1      Nucleus               Transcription regulator
                                                                             --1.261   CCND2      Nucleus               Other
                                                                             --1.099   CD44       Plasma Membrane       Other
                                                                             0.953     CD55       Plasma Membrane       Other
                                                                             --1.914   CDKN2B     Nucleus               Transcription regulator
                                                                             0.879     CEBPD      Nucleus               Transcription regulator
                                                                             --1.19    CEL        Extracellular Space   Enzyme
                                                                             --1.443   CHRNA5     Plasma Membrane       Transmembrane receptor
                                                                             2.434     CHRNB1     Plasma Membrane       Transmembrane receptor
                                                                             3.049     CNR1       Plasma Membrane       G-protein coupled receptor
                                                                             --1.606   COL18A1    Extracellular Space   Other
                                                                             --1.411   COL1A1     Extracellular Space   Other
                                                                             --1.683   COL1A2     Extracellular Space   Other
                                                                             --1.979   COL3A1     Extracellular Space   Other
                                                                             --0.757   COL4A1     Extracellular Space   Other
                                                                             --0.879   COL4A2     Extracellular Space   Other
                                                                             --1.037   COL5A1     Extracellular Space   Other
                                                                             --0.883   COL5A2     Extracellular Space   Other
                                                                             --1.291   COL5A3     Extracellular Space   Other
                                                                             --0.693   COL6A1     Extracellular Space   Other
                                                                             --1.028   COL6A3     Extracellular Space   Other
                                                                             --1.023   COL8A1     Extracellular Space   Other
                                                                             0.586     CPT1A      Cytoplasm             Enzyme
                                                                             1.683     CRP        Extracellular Space   Other
                                                                             0.823     CST3       Extracellular Space   Other
                                                                             --2.373   CTSK       Cytoplasm             Peptidase
                                                                             --1.26    CXCL12     Extracellular Space   Cytokine
                                                                             --0.965   CYP11A1    Cytoplasm             Enzyme
                                                                             2.541     CYP2E1     Cytoplasm             Enzyme
                                                                             --1.687   CYP7B1     Cytoplasm             Enzyme
                                                                             --0.808   Dclk1      Cytoplasm             Kinase
                                                                             1.204     DECR1      Cytoplasm             Enzyme
                                                                             0.926     DKK3       Extracellular Space   Cytokine
                                                                             --1.807   DPP4       Plasma Membrane       Peptidase
                                                                             1.335     DRD4       Plasma Membrane       G-protein coupled receptor
                                                                             --0.918   EIF2AK2    Cytoplasm             Kinase
                                                                             1.828     EIF4EBP1   Cytoplasm             Translation regulator
                                                                             --0.766   EPHA4      Plasma Membrane       Kinase
                                                                             1.681     FABP1      Cytoplasm             Transporter
                                                                             --0.902   FABP5      Cytoplasm             Transporter
                                                                             --1.589   FBN1       Extracellular Space   Other
                                                                             --1.834   FBN2       Extracellular Space   Other
                                                                             0.68      FDFT1      Cytoplasm             Enzyme
                                                                             --0.97    FLNA       Cytoplasm             Other
                                                                             --0.801   FYN        Plasma Membrane       Kinase
                                                                             3.723     GAL        Extracellular Space   Other
                                                                             --1.286   GAP43      Plasma Membrane       Other
                                                                             1.627     GCKR       Nucleus               Other
                                                                             1.926     GDF15      Extracellular Space   Growth factor
                                                                             --0.697   GFM1       Cytoplasm             Translation regulator
                                                                             1.799     GLRB       Plasma Membrane       Ion channel
                                                                             --1.371   GPD2       Cytoplasm             Enzyme
                                                                             1.401     GPNMB      Plasma Membrane       Enzyme
                                                                             0.725     GUCY1A3    Cytoplasm             Enzyme
                                                                             0.855     HADHA      Cytoplasm             Enzyme
                                                                             0.593     HADHB      Cytoplasm             Enzyme
                                                                             1.203     HBG2       Cytoplasm             Other
                                                                             --1.033   HK2        Cytoplasm             Kinase
                                                                             0.846     HMGCL      Cytoplasm             Enzyme
                                                                             --0.703   HMGCR      Cytoplasm             Enzyme
                                                                             3.441     HMGCS2     Cytoplasm             Enzyme
                                                                             --1.702   HOMER1     Plasma Membrane       Other
                                                                             1.727     HP         Extracellular Space   Peptidase
                                                                             --1.439   HRH1       Plasma Membrane       G-protein coupled receptor
                                                                             3.249     HSPA1L     Cytoplasm             Other
                                                                             --0.714   HSPB1      Cytoplasm             Other
                                                                             1.882     HTR1D      Plasma Membrane       G-protein coupled receptor
                                                                             0.894     ID1        Nucleus               Transcription regulator
                                                                             --0.657   IGF1       Extracellular Space   Growth factor
                                                                             0.675     IGF1R      Plasma Membrane       Transmembrane receptor
                                                                             1.624     IGFBP3     Extracellular Space   Other
                                                                             --2.072   IGFBP5     Extracellular Space   Other
                                                                             0.664     IL1R1      Plasma Membrane       Transmembrane receptor
                                                                             1.38      INSIG1     Cytoplasm             Other
                                                                             0.95      INSR       Plasma Membrane       Kinase
                                                                             --1.237   KCNAB3     Plasma Membrane       Ion channel
                                                                             --0.611   KCNJ11     Plasma Membrane       Ion channel
                                                                             0.764     KCNK3      Plasma Membrane       Ion channel
                                                                             1.819     KCTD16     Plasma Membrane       Other
                                                                             1.063     KLF10      Nucleus               Transcription regulator
                                                                             --0.613   KRAS       Cytoplasm             Enzyme
                                                                             2.749     LEPR       Plasma Membrane       Transmembrane receptor
                                                                             --0.69    LIMS1      Plasma Membrane       Other
                                                                             1.168     LIPC       Extracellular Space   Enzyme
                                                                             0.887     LRP8       Plasma Membrane       Transmembrane receptor
                                                                             --1.079   MAGI3      Cytoplasm             Kinase
                                                                             --1.167   MAOB       Cytoplasm             Enzyme
                                                                             --0.87    MEOX2      Nucleus               Transcription regulator
                                                                             --0.634   MGP        Extracellular Space   Other
                                                                             1.685     MS4A6A     Other                 Other
                                                                             --1.838   MSTN       Extracellular Space   Growth factor
                                                                             2.404     NEFH       Cytoplasm             Other
                                                                             --2.808   NOS2       Cytoplasm             Enzyme
                                                                             0.816     NOTCH4     Plasma Membrane       Transcription regulator
                                                                             --0.977   NRAS       Plasma Membrane       Enzyme
                                                                             1.836     NTRK1      Plasma Membrane       Kinase
                                                                             2.42      OLR1       Plasma Membrane       Transmembrane receptor
                                                                             --1.059   OPRD1      Plasma Membrane       G-protein coupled receptor
                                                                             --1.268   OXCT1      Cytoplasm             Enzyme
                                                                             2.329     PAK1       Cytoplasm             Kinase
                                                                             0.7       PECAM1     Plasma Membrane       Other
                                                                             1.068     PIK3IP1    Cytoplasm             Other
                                                                             2.175     PKLR       Cytoplasm             Kinase
                                                                             --2.188   PLPP3      Plasma Membrane       Phosphatase
                                                                             0.697     POR        Cytoplasm             Enzyme
                                                                             --0.754   PPT2       Cytoplasm             Enzyme
                                                                             --0.61    PRKCA      Cytoplasm             Kinase
                                                                             --0.713   PRKCB      Cytoplasm             Kinase
                                                                             0.894     PSMD8      Cytoplasm             Other
                                                                             --1.882   PTGIS      Cytoplasm             Enzyme
                                                                             --1.791   QPCT       Cytoplasm             Enzyme
                                                                             --1.546   RAMP3      Plasma Membrane       Transporter
                                                                             --3.845   RET        Plasma Membrane       Kinase
                                                                             --0.767   S100A10    Cytoplasm             Other
                                                                             1.12      S100B      Cytoplasm             Other
                                                                             --0.842   SERPINE2   Extracellular Space   Other
                                                                             --0.833   SERPINF1   Extracellular Space   Other
                                                                             --0.586   SET        Nucleus               Phosphatase
                                                                             2.599     SLC12A1    Plasma Membrane       Transporter
                                                                             2.338     SLC12A3    Plasma Membrane       Transporter
                                                                             --1.043   SLC2A4     Plasma Membrane       Transporter
                                                                             1.018     SLC9A1     Plasma Membrane       Ion channel
                                                                             --0.882   SLCO2A1    Plasma Membrane       Transporter
                                                                             0.834     SORL1      Cytoplasm             Transporter
                                                                             1.193     SOX2       Nucleus               Transcription regulator
                                                                             0.936     SQSTM1     Cytoplasm             Transcription regulator
                                                                             2.28      SSTR2      Plasma Membrane       G-protein coupled receptor
                                                                             0.737     SSTR3      Plasma Membrane       G-protein coupled receptor
                                                                             2.067     STAR       Cytoplasm             Transporter
                                                                             0.641     TANGO2     Cytoplasm             Other
                                                                             1.49      TGFBR3     Plasma Membrane       Kinase
                                                                             --2.148   TGM1       Plasma Membrane       Enzyme
                                                                             --0.6     THBD       Plasma Membrane       Transmembrane receptor
                                                                             0.734     THRB       Nucleus               Ligand-dependent nuclear receptor
                                                                             0.828     TIMP3      Extracellular Space   Other
                                                                             --3.057   TLR7       Plasma Membrane       Transmembrane receptor
                                                                             --0.685   TMEM116    Other                 Other
                                                                             0.736     TNNT2      Cytoplasm             Other
                                                                             --2.696   TOP2A      Nucleus               Enzyme
                                                                             --0.705   TP53       Nucleus               Transcription regulator
                                                                             2.123     TSPAN5     Plasma Membrane       Other
                                                                             --0.83    TUBA8      Cytoplasm             Other
                                                                             0.823     XDH        Cytoplasm             Enzyme

Green indicates the downregulated gene; red indicates the upregulated gene.

Pathway Analysis and Pathophysiological Mechanisms {#s3-3}
--------------------------------------------------

The contribution of every DEGs to the development of diastolic dysfunction was calculated in the context of molecular network and biological progresses using the algorithms described in the Materials and Methods section.

### Dahl/SS {#s3-3-1}

The biological activities occurring in the heart tissue were identified using the IPA Upstream Regulator analytic on the gene expression changes we observed in the dataset. The analysis inferred the likely activation states of 5 transcription regulators given by our DEG dataset. Hence, based on the comparison of the change of direction of the DEGs (i.e., expression in the Dahl/SS model to control) and what is known from the literature we found that the transcription regulators *TGFB1*, *RETNLB*, *TNF*, *INHBA*, and *IL17RA* (*z*-score 2.4, 2.2, 2.1, 2.0, 2.0, respectively) were predicted to be activated ([Figure 1](#F1){ref-type="fig"}). A further examination of the underlying biological activities prompted by our dataset from the hearts of Dahl/SS rats revealed biological activities such as dilated cardiomyopathy, hypertrophy of heart, arrhythmia, and failure of heart ([Figure 2](#F2){ref-type="fig"}).

![Top predicted activation state in Dahl SS. Asterisks (\*) indicate that multiple identifiers in the dataset file map to a single gene in the Global Molecular Network. Figure has been generated using Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Inc., Cambridge, MA, USA).](fcvm-05-00011-g001){#F1}

![Top pathological functions in Dahl/SS. Asterisks (\*) indicate that multiple identifiers in the dataset file map to a single gene in the Global Molecular Network. Figure has been generated using Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Inc., Cambridge, MA, USA).](fcvm-05-00011-g002){#F2}

### SHHF {#s3-3-2}

A total of 186 DEGs were observed. Of the 78 significantly upregulated genes, 43 fell into the rather nondescript category of "other", followed by 10 in the second largest group transcription regulator. Of the 108 downregulated genes, 61 were characterized as "other", 17 as enzyme, and 6 as transcription regulator. Differently from the Dahl/SS, the SHHF model did not show significant inferred activation of upstream transcription regulators, apart from a moderate activation (*z*-score 0.3) of *NUPR1*. In this model, the *ERBB2* upstream regulator was predicted to be inhibited (*z*-score −2.2). As shown in [Figure 3](#F3){ref-type="fig"}, ERBB2 is a plasma membrane-bound receptor tyrosine kinases that is involved in the protection of cardiac myocytes, which is illustrated by the cardiotoxicity of ERBB2-targeted cancer therapies ([@B13]). Out of the 250 DEGs determined in the SHHF heart tissue, 26 genes were linked to cardiovascular disease including cardiotoxicity, pericarditis, ST-elevated myocardial infarction, and dilated cardiomyopathy. A list of these genes is provided in [Table 3](#T3){ref-type="table"}.

![Significant inhibition of ERBB2 kinase in SHHF. Asterisks (\*) indicate that multiple identifiers in the dataset file map to a single gene in the Global Molecular Network. Figure has been generated using Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Inc., Cambridge, MA, USA).](fcvm-05-00011-g003){#F3}

### Diabetic 1 {#s3-3-3}

The diabetic rat model resulted in the highest number of DEGs (see [Table 1](#T1){ref-type="table"}) consistent with a FDR = 0. A total of 18 (9 activated and 9 inhibited) significant upstream transcriptional regulators that can explain the observed gene expression profile were identified. A list of these genes is displayed in [Table 5](#T5){ref-type="table"}. Not surprisingly, given the metabolic underpinnings of the model, most (110) of the 558 genes that were upregulated code for enzymes. Other groupings include 30 kinases, 20 G-protein-coupled receptors, 18 ion channels, and 6 growth factors. Upregulated as well is *NPPA* encoding for atrial natriuretic peptide (ANP), a biomarker for cardiac hypertrophy and heart failure ([Figure 4](#F4){ref-type="fig"}). Two genes that code for recently proposed novel biomarkers for HFpEF were also upregulated: *HSPB1*, which codes for cardioprotective heat shock protein 27 (hsp27) ([@B14],[@B15]) and *ANG* which codes for angiogenin, a protein important for vascularization ([@B16]).

###### 

Significant upstream transcriptional regulators in the diabetic rat model

  **Upstream Regulator**                         **Molecule Type**         **Predicted Activation State**   **Activation z-score**   **Target molecules in dataset**
  ---------------------------------------------- ------------------------- -------------------------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  RABL6                                          Other                     Inhibited                        −2,010                   ABAT,AURKB,BIK,CCNB1,DAPK1,H2AFX,MCM5,MCM7,RFC3,SERPINH1,TOP2A,TP53
  MAX                                            Transcription regulator   Inhibited                        −2,000                   CCND2,CDKN2B,FBXO32,GADD45B,KLF10,TMEM126A,TXNIP
  HLX                                            Transcription regulator   Inhibited                        −2,000                   BMP2,CCNB1,CYP1B1,GDF15
  IFNL1                                          Cytokine                  Inhibited                        −2,186                   EIF2AK2,IFI35,MX1,UBE2L6,USP18
  MNT                                            Transcription regulator   Inhibited                        −2,000                   FBXO32,GADD45B,KLF10,TXNIP
  IFNG                                           Cytokine                  Inhibited                        −2,668                   ALOX15,ASS1,BCL2L1,CASP8,CAT,Ccl2,CCL22,CYP2E1,DDR2,DPP4,EIF2AK2,ICOSLG/LOC102723996,IFIT1B,LOX,MX1,NOS2,NPY2R,SDC4,SERPINB9,SLC15A3,STAR,TGM1,TXNIP,UBD,USP18
  IFNA2                                          Cytokine                  Inhibited                        −2,068                   EIF2AK2,IFI35,IFNB1,MX1,TP53,UBE2L6,USP18
  PCDH11Y                                        Other                     Inhibited                        −2,236                   CCND1,CCND3,CD44,GJA1,RET
  SPDEF                                          Transcription regulator   Activated                        2,496                    CDH11,COL1A1,COL4A1,COL4A2,COL5A1,COL5A2,COL6A1,COL6A3,DKK3,EGFR,ITGA6,LAMC1,PRKCA,SMAD3
  KIAA1524                                       Other                     Activated                        2,359                    C4BPA,CDKN2B,COL8A1,ENO3,GPNMB,LUM,RHOC,SERPINE2,TUBA4A
  miR-29b-3p (and other miRNAs w/seed AGCACCA)   Mature microrna           Activated                        2,449                    COL1A2,COL5A2,GAS7,LAMC1,MYBL2,TUBB2A
  CST5                                           Other                     Activated                        2,584                    ACAT2,AKAP12,AP1M2,CAV1,CD44,DECR1,DRAP1,ELK3,EMP3,EPN3,FER,FHL1,LAMC1,NR2F1,NRP1,PLS3,PRSS8,S100A11,TAF1,TGIF1,TSPAN5,VCAN
  PTGS2                                          Enzyme                    Activated                        2,425                    BCL2L1,Ccl2,IFNB1,ITGA6,MCL1,MMP14,PPA1,TP53
  SIRT1                                          Transcription regulator   Activated                        2,049                    ATXN10,BNIP3,CCND2,CPT1A,CYP1A1,HMGCR,IGF1,TP53
  KITLG                                          Growth factor             Activated                        2,000                    BCL2L1,IL1RL1,PRKCA,PRKCB
  FOXO3                                          Transcription regulator   Activated                        2,197                    BNIP3,CAT,CCND2,CDKN2B,EGR4,FBXO32,GADD45B,MXI1,TXNIP
  NEDD9                                          Other                     Activated                        2,646                    BMP2,BNIP3,ELF3,FABP1,GDF15,MMP14,TXNIP
  POU2F2                                         Transcription regulator   Activated                        2,236                    ALDOC,KCNN4,MCM7,PFKFB3,SSTR2,VIP

Orange/blue indicate the predicted activation state, namely activated/inhibited, of the transcriptional regulator.

![Pathological processes in the diabetic rat model. Asterisks (\*) indicate that multiple identifiers in the dataset file mapto a single gene in the Global Molecular Network. Figure has been generated using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc., Cambridge, MA, USA).](fcvm-05-00011-g004){#F4}

Discussion {#s4}
==========

In our study, we selected three established rat models of diastolic dysfunction that are defined by three major risk factors associated with HFpEF. Remarkably, we found that the cardiac transcriptomics of the models demonstrated little commonality, either in differentially regulated genes or specific biological functions. Overall, our findings highlight the case that divergent molecular processes may underpin a shared phenotype.

Diastolic dysfunction is primarily characterized by stiffening of the left ventricular (LV) tissue, which contributes to impaired relaxation and filling of the ventricle. The specific mechanisms leading to myocardial stiffening are undetermined, but broadly LV stiffness has active and passive components. Passive stiffness describes the inherent stretchiness of the myocardium and is governed by the pliability of both the extracellular matrix and the contractile units. The latter is set by the giant sarcomeric filament, titin, which also determines the elastic recoil of the myocardium, thereby contributing in a major way to LV filling *via* diastolic suction ([@B17]). Evidence indicates that abnormal high-energy phosphate metabolism, specifically increased free cytosolic ADP and enhanced AMP catabolism, may contribute to passive myocardial diastolic stiffness as well ([@B18],[@B19]).

Active stiffness, or reduced relaxation, of the LV tissue depends on Ca^2+^ homeostasis ([@B20]). There are two interrelated aspects of intracellular Ca^2+^ handling that determine diastolic function; the rate of cytosolic Ca^2+^ decline following its release from the sarcoplasmic reticulum (SR), and the resting or end-diastolic Ca^2+^ concentration ([@B21]). These parameters are set by the rate of Ca^2+^ removal from the cell *via* the sodium calcium exchanger (NCX) and reuptake of Ca^2+^ into stores by SERCA2, in addition to Ca^2+^ leak from the SR. We did not observe any changes in the gene expression of calcium handling proteins (SERCA2, NCX, PLN, or CASQ2) in any of the three models of diastolic dysfunction. Of course, our approach does not address the possibility that in any of the models of diastolic dysfunction the activities of the Ca^2+^ handling protein are negatively affected by posttranslational modification or change in their environment.

[Figure 1](#F1){ref-type="fig"} displays the targets of TGFB1 that are differentially expressed in the Dahl/SS dataset. TGFB1 plays a central role in hypertension-induced cardiac hypertrophy and fibrosis ([@B22],[@B23]), and consistent with that fact, genes involved in fibrosis/extracellular matrix (ECM) accumulation (*TGFB1*, *POSTN*, *CTGF*, *TIMP1*) ([@B24]) and hypertension-related pathological hypertrophy (*NPPA* and *MYH7*) ([@B25]--[@B28]) are upregulated with hypertension. Interestingly, the Dahl/SS model of heart failure is associated with upregulation of the Wnt signaling inhibitor secreted frizzled-related protein-1 (*SFRP1*), which protects against ventricular dilation and hypertrophy ([@B29]), as well as increased expression of the transporter of large neutral amino acids (*SLC7A5*). Downstream targets of TGFB1 upregulated in Dahl/SS rats include *EGR2* and *NUPR1*. Based on computational analysis of the transcriptomes at five time points in male murine hearts subjected to transverse aorta banding, the transcription factor EGR2 was recently identified as a new candidate key regulator of cardiovascular-associated genes ([@B30]). Nupr1 is a nuclear basic helix-loop-helix protein and transcriptional coregulator that is induced in response to stress in the heart ([@B31]). Recent evidence indicates that Nupr1 activation contributes to cardiac fibrosis, while protecting against autophagy and apoptosis that lead to heart failure ([@B32]). Elevated circulating levels of both interleukin (IL)-6 and TNF are observed in HFpEF ([@B33]), and in the Dahl/SS model TNF shares several downstream targets with TGFB1, including *TIMP1*, *INHBA*, and *SFRP1* ([Figure 1](#F1){ref-type="fig"}). The role of INHBA or RETNLB in cardiac remodeling is unreported. The predicted downstream target of RETNLB, THBS4, has been shown to attenuate pressure-overload cardiac fibrosis ([@B34]). TNF is also linked to *S100A9* and *S100A8* expression (both significantly increased in our DEG list), as is *IL17RA* (Interleukin 17 receptor A). IL17RA has been linked to myocardial collagen metabolism in hypertension-induced diastolic dysfunction and heart failure ([@B35],[@B36]). The "damage-associated molecular patterns" (DAMPs), proteins S100A8/A9 contribute to cardiac fibrosis by activating pro-inflammatory NF-κB signaling in cardiac fibroblasts *via* the receptor for advanced glycation end products (RAGE) and inducing the expression of multiple chemokines and cytokines ([@B37]). NF-κB is predicted to be activated in the Dahl/SS model (z-score of 1.92), as evidenced by the marked upregulation of *CTGF*, *CXCL11*, *SLC7A5*, *TIMP1*, and *CDC25B*. TNF is also linked to upregulation of the chemokine CXCL11 and the hormone Apelin, which appear to have conflicting actions on cardiac inflammation ([@B38]) and hypertrophy ([@B39]), respectively. Interestingly, TNF is linked to upregulation of Purkinje cell protein-4 (*PCP4*), a putative regulator of calmodulin and Ca^2+^/calmodulin-dependent kinase II (CaMKII) signaling, within the His-Purkinje network and contributor to cardiac arrhythmias ([@B40]). The role if any played by *DNER*, *REG3A*, and *IRX1* to diastolic dysfunction and cardiac hypertrophy is not reported, although genetic variants of the *IRX1* gene were recently reported to contribute to the pathogenesis of congenital heart disease ([@B41]). Finally, expression levels of CXCL11 were increased in hearts of Dahl/SS rats fed a high salt diet, which is consistent with the concept that inflammation plays a key role in the pathogenesis of HFpEF. The closely related CXCL9, CXCL10, and CXCL11 are chemoattractants for monocytes and lymphocytes. Accumulating evidence has implicated these chemokines in several cardiovascular diseases, including atherosclerosis, hypertension, cardiac hypertrophy, and heart failure, as well as in transplant coronary artery disease and heart transplant rejection ([@B42]). Of note, circulating levels of these chemokines were found to provide additional diagnostic utility beyond NT-pro BNP levels for detecting LV diastolic dysfunction in hypertensive patients ([@B43]). In addition, we observed that serum levels of CXCL10 are increased in patients with symptomatic heart failure ([@B44]). Although CXCL9, -10, and -11 all bind to CXCR3, there is some evidence that these agonists activate opposing responses due to biased signaling that is a fixture of G protein-coupled receptors ([@B44]). Whereas CXCL9/CXCL10/CXCR3 interactions drive effector Th1 polarization, CXCL11/CXCR3 binding seems to induce an immunotolerizing state characterized by polarization into regulatory Tr1 lymphocytes that produce anti-inflammatory IL-10.

For the SHHF dataset, none of the DEGs stood out mechanistically in the context of heart failure. Expression of the gene for frizzled class receptor 5 (*FZD5*), which plays a role in endothelial cells in angiogenesis ([@B45]), was increased, as was the gene for the repressor of the protective, anti-oxidant transcription factor Nrf2, *KEAP1* ([@B46]).

Unexpectedly, the genes for 9 different collagen types were downregulated in diabetic 1 hearts, although a number of genes involved in ECM remodeling and fibrosis were upregulated, including *MMP14* ([@B24]), as well as *SDC4* and *LOX*, which together have been linked to myocardial stiffness and diastolic dysfunction ([@B47]). *PDGFD*, which codes for platelet-derived growth factor D, a potent pro-fibrotic cytokine ([@B48]), was upregulated. Two signaling components of the pro-fibrotic cytokine TGF-β were upregulated, *SMAD3* ([@B49]) and *TGFBR3* (TGF-β receptor 3), although *TGFBR1* (TGF-β receptor 1) was downregulated and the inhibitory *SMAD7* was upregulated. However, *CAV*1 was downregulated. *CAV1* encodes for caveolin 1, which may inhibit both TGF-β-dependent and --independent cardiac fibrosis ([@B50]). Other relevant pro-fibrotic genes that were upregulated, include: the chemokines *CCL2* and *CXCL3*, linked to fibrosis and inflammation ([@B51]--[@B53]); pro-inflammatory cytokine *Il-3* ([@B54]) and the innate immune cytokine *IFNB1*; and the K^+^ channel *KCNN4*, which is linked to angiotensin II-induced cardiac fibroblast proliferation and collagen production ([@B55]). The gene for the tyrosine kinase receptor EGFR was also upregulated. EGFR is implicated in cardiac fibrosis and hypertrophy ([@B56]--[@B58]), as well as heart protection ([@B59]). In contrast, the gene for TIMP3, which has anti-fibrotic actions ([@B60]), was upregulated. Several pro-fibrotic genes were downregulated, including: *VCAN* (Versican) ([@B61]); *LUM* (Lumican), an ECM-localized proteoglycan that binds collagen and is important for fibrosis, is associated with inflammation, and is increased in experimental and clinical heart failure ([@B62]); *SERPINE2*, which is increased in pressure overload- and angiotensin II-induced cardiac remodeling downstream of ERK1/2 signaling and increases collagen deposition ([@B63]); and the integrin *ITGA6*, associated with collagen deposition ([@B64]).

Notable genes linked to metabolism were increased in diabetic hearts, including *FABP1* and *GDF15*. The later encodes a heart-derived hormone, which regulates body growth ([@B65]). *PFKFB3* encodes a pro-glycolytic enzyme that is upregulated in cardiac progenitor cells by diabetes ([@B66]). The gene for the leptin receptor (*LEPR*), which is implicated to both cardiac hypertrophy and cardioprotection in obesity ([@B67]), was upregulated. However, a number of genes associated with cardiac hypertrophy and heart failure due to pressure-overload or angiotensin II infusion were downregulated. *CCND2* (cyclin D2), which was implicated in cardiac hypertrophy, was downregulated ([@B68]), but so was the cyclin-dependent kinase inhibitor *CDKN2B. TP53*, a major player in the development of systolic heart failure ([@B69],[@B70]), was downregulated, as was *PRKCA*. Activation of PKCα is implicated in cardiac hypertrophy and heart failure ([@B71]--[@B73]).

Oxidative stress is a feature of the diabetic heart ([@B74]) and several genes associated with inflammation and oxidative stress were upregulated. *CAT*, encoding the key antioxidant enzyme catalase was upregulated. On the other hand, *TXNIP*, which inhibits the anti-oxidative function of thioredoxin, was also upregulated. TXNIP is linked to increased oxidative stress, along with fibrosis and arrhythmias in diabetes ([@B75]), as well as diabetic cardiomyopathy ([@B76]). The thioredoxin system 2 is a major buffer against H~2~O~2~ emission from mitochondria ([@B77]), and the present evidence showing that *TXNIP* is strongly upregulated in the diabetic heart may account for the overall oxidative environment found in the diabetic heart.*TSPAN5*, encoding a cell surface protein was upregulated. Evidence was recently reported that endothelial Tspan5- and Tspan17-ADAM10 complexes contribute to inflammation by maintaining VE-cadherin expression and promoting T lymphocyte transmigration ([@B78]). Another injury-related gene that was upregulated was *BNIP3*, which is associated with mitochondrial autophagy and apoptosis and is increased in the heart by pressure overload and various stresses ([@B79],[@B80]).

Notably, a number of protective genes were upregulated in the type 1 diabetic heart. The gene for the Smad corepressor, transforming growth interacting factor (*TGIF*) was increased, as was *BMP2*. BMP2 may antagonize BMP4-induced cardiomyocyte hypertrophy and apoptosis ([@B81]) and TGF-β-induced fibrosis ([@B82]). Three genes linked to inhibition of cardiac hypertrophy were upregulate, *viz.*, *DKK3* (Dickkopf-3) ([@B83]), *FBXO32* (encoding E3 ligase, Fbxo32) ([@B84]), and *GADD45B*, which blocks MKK7-induced JNK activation ([@B85]). The anti-apoptotic gene *BCL2L1* ([@B86]) was upregulated, as well as *MCL1*, which is important in mitochondrial function and autophagy ([@B87]). *VIP* (vasoactive intestinal peptide), cardioprotective in heart failure ([@B88]), and *SMAD5*, which has anti-apoptotic actions in cardiac myocytes ([@B89]) were upregulated. On the other hand, *AKAP12*, which may protect against IR injury ([@B90]), was downregulated, as were both *MYBL2* and *TUBB2A*, which were recently shown to be upregulated in the heart after acute MI ([@B91],[@B92]).

Interestingly, we found that there were no genes similarly affected among all three models of diastolic dysfunction, nor between the Dahl SS and SHHF models. However, the type 1 diabetes model shared 20 regulated genes with the Dahl SS model and 15 with the SHHF model. Human diseases traditionally have been differentiated and categorized on the basis of which organ system they primarily affect. An alternate view is now emerging, which emphasizes that different diseases typically have common underlying mechanisms and intermediate pathophenotypes or endo(pheno)types. According to this construct, expression of a specific disease reflects the interplay between relevant endophenotypes and the local organ-based environment. Important examples of such endophenotypes are inflammation, fibrosis, and metabolic dysfunction, which play essential roles in many developing diseases. In this study, we identified the endophenotype networks of three models of diastolic dysfunction and explored their relation to cardiovascular diseases in particular. We identified the subnetworks of the top regulated microarray genes that are playing a role in inflammation, fibrosis, and metabolism. Although our three models of diastolic dysfunction exhibit little overlap in regulated genes, each is still significantly enriched with disease-associated genes. Moreover, they are enriched also with differentially expressed genes linked to cardiovascular disease (risk).

Our findings illustrate as well the observation that HFpEF is a syndrome with multiple extracardiac comorbidities, such as aging, hypertension, and obesity, rather than a disease of clearly defined etiology ([@B93]). Pharmacological targeting of HFpEF may need to be informed more by phenotypic characteristics of the cardiac remodeling events that occur than by the underlying molecular processes alone. These phenotypic events may include concentric hypertrophy, myocardial stiffness, fibrosis, endothelial dysfunction, capillary rarefaction, and abnormal ventricular-arterial coupling, as well as changes in the shape and stiffness of the left atrium.

There are some limitations and caveats to our approach. Changes in gene expression may not necessarily be reflective of changes in protein levels, given the contribution of additional levels of post-transcriptional regulation, including microRNA mediated regulation. Alterations in protein stability and function may occur as well. In addition, in any disease context, changes in gene expression have a temporal and dynamic component, with alterations in expression of any particular gene and its protein levels at a given time point being impacted upon by changes in other network or system components. Nonetheless, global changes in gene expression are reflective of basic underlying pathological processes and offer insight into stress-related responsiveness to the disease process. In addition, there are several other models of HFpEF, such as abdominal aortic constriction and partial nephrectomy. Certainly, it would be of interest to extend our analysis in the future to include these other models. It should be mentioned as well that streptozotocin affects other organ systems, including vascular function; however, HFpEF in many patients is increasingly recognized as a systemic disorder involving vascular inflammation and dysfunction ([@B94]).

In conclusion, our *in silico* analysis of differential gene expression in three common rat models of diastolic dysfunction highlights the diversity in causality and molecular basis for the impaired cardiac function. A better understanding of the phenotype changes that accompany diastolic dysfunction, such as concentric hypertrophy, and their impact on genetic changes, is required to gain better insight into the disease process. An effective pharmacological approach for diastolic dysfunction and HFpEF may arise from a global strategy based on a better understanding of altered cardiac ultrastructure.
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